MCID: GNR004
MIFTS: 49

Generalized Anxiety Disorder

Categories: Mental diseases

Aliases & Classifications for Generalized Anxiety Disorder

MalaCards integrated aliases for Generalized Anxiety Disorder:

Name: Generalized Anxiety Disorder 12 52 14 69
Anxiety Generalized 52

Classifications:



External Ids:

Disease Ontology 12 DOID:14320
ICD10 33 F41.1
ICD9CM 35 300.02
NCIt 47 C92622
UMLS 69 C0270549

Summaries for Generalized Anxiety Disorder

Disease Ontology : 12 An anxiety disorder that is characterized by long-lasting anxiety that is not focused on any one object or situation.

MalaCards based summary : Generalized Anxiety Disorder, also known as anxiety generalized, is related to personality disorder and schizophrenia. An important gene associated with Generalized Anxiety Disorder is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Circadian rythm related genes and cAMP signaling pathway. The drugs Alprazolam and Valproic Acid have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and heart, and related phenotypes are Decreased viability and behavior/neurological

Wikipedia : 72 Generalized anxiety disorder (GAD) is an anxiety disorder characterized by excessive, uncontrollable and... more...

Related Diseases for Generalized Anxiety Disorder

Diseases related to Generalized Anxiety Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 119)
id Related Disease Score Top Affiliating Genes
1 personality disorder 27.7 BDNF DRD2 HTR1A HTR2A MAOA PSMD9
2 schizophrenia 26.2 BDNF DRD2 HTR1A HTR2A HTR3A MAOA
3 anxiety disorder 11.5
4 paranoid personality disorder 10.6 HTR1A HTR2A
5 polyneuropathy 10.6 HTR1A HTR2A
6 hodgkin's granuloma 10.5 HTR1A HTR2A
7 conjunctival pigmentation 10.4 MAOA SLC6A4
8 conjunctival degeneration 10.4 HTR1A HTR2A SLC6A4
9 panic disorder 10.4
10 neurogenic bladder 10.4 HTR2A MAOA SLC6A4
11 pervasive developmental disorder 10.3 BDNF SLC6A2 SLC6A4
12 chromosome 11p13 deletion syndrome, distal 10.3 BDNF HTR2A SLC6A4
13 abnormal pupillary function 10.3 HTR1A HTR3A
14 tinea pedis 10.3 HTR1A MAOA SLC6A4
15 intracranial cavernous angioma 10.3 DRD2 SLC6A4
16 vallecula cancer 10.2 HTR1A MAOA SLC6A4
17 anodontia 10.2 HTR1A HTR3A SLC6A4
18 splenic abscess 10.2 DRD2 HTR2A SLC6A4
19 hyperthyroxinemia 10.2 DRD2 HTR2A SLC6A4
20 teebi kaurah syndrome 10.2 DRD2 HTR2A
21 hyperimmunoglobulin syndrome 10.2 HTR1A HTR3A
22 social phobia 10.2
23 luxation of globe 10.2 HTR1A SLC6A4
24 obsessive-compulsive disorder 10.2
25 mandibular cancer 10.2 HTR1A HTR3A SLC6A4
26 primary angle-closure glaucoma 10.2 BDNF HTR1A HTR2A SLC6A4
27 anosognosia 10.2 DRD2 HTR1A SLC6A4
28 testicular lymphoma 10.1 BDNF HTR1A TSPO
29 hepatic angiomyolipoma 10.1 BDNF HTR2A SLC6A2 SLC6A4
30 contact dermatitis 10.1 DRD2 HTR2A
31 allergic hypersensitivity disease 10.1 DRD2 HTR1A HTR2A
32 perinatal necrotizing enterocolitis 10.1 BDNF DRD2 SLC6A4
33 vascular cancer 10.1 DRD2 HTR1A HTR2A
34 hallucinogen dependence 10.1 BDNF DRD2 SLC6A4
35 alcoholic liver cirrhosis 10.1 BDNF DRD2 SLC6A4
36 intrahepatic gall duct cancer 10.1 BDNF HTR2A MAOA SLC6A4
37 agoraphobia 10.1
38 tongue disease 10.1 DRD2 MAOA SLC6A4
39 chronic dacryoadenitis 10.1 BDNF HTR1A MAOA SLC6A4
40 eosinophilia-myalgia syndrome 10.0 BDNF DRD2
41 ulcerative colitis 10.0 BDNF DRD2
42 pompholyx 9.9 DRD2 HTR1A HTR2A SLC6A4
43 laryngeal adductor paralysis 9.9 HTR1A HTR2A SLC6A4 TPH1
44 suppurative periapical periodontitis 9.9 DRD2 SLC6A4 TPH1
45 heart disease 9.9
46 pyromania 9.9 DRD2 HTR2A MAOA SLC6A4
47 transsexualism 9.9 BDNF HTR1A HTR3A TSPO
48 hemorrhagic cystitis 9.9 DRD2 MAOA SLC6A2 SLC6A4
49 osteogenesis imperfecta, type ix 9.8 BDNF DRD2 HTR3A
50 dysthymic disorder 9.8

Comorbidity relations with Generalized Anxiety Disorder via Phenotypic Disease Network (PDN): (show all 18)


Acute Cystitis Anxiety Disorder
Bronchitis Chronic Myocardial Ischemia
Dependent Personality Disorder Dysthymic Disorder
Esophagitis Histrionic Personality Disorder
Hypertension, Essential Hypochondriasis
Hypothyroidism Irritable Bowel Syndrome
Obsessive-Compulsive Disorder Obsessive-Compulsive Personality Disorder
Osteoporosis Personality Disorder
Schizophreniform Disorder Somatization Disorder

Graphical network of the top 20 diseases related to Generalized Anxiety Disorder:



Diseases related to Generalized Anxiety Disorder

Symptoms & Phenotypes for Generalized Anxiety Disorder

GenomeRNAi Phenotypes related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.1 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.1 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Generalized Anxiety Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.15 BDNF CRHR1 DRD2 HTR1A HTR2A HTR3A
2 cardiovascular system MP:0005385 9.97 SLC6A2 SLC6A4 TPH1 TSPO CRHR1 DRD2
3 homeostasis/metabolism MP:0005376 9.85 BDNF CRHR1 DRD2 HTR1A HTR3A MAOA
4 endocrine/exocrine gland MP:0005379 9.8 SLC6A4 TSPO BDNF CRHR1 DRD2 HTR2A
5 muscle MP:0005369 9.43 DRD2 HTR2A HTR3A RGS2 SLC6A4 TPH1
6 nervous system MP:0003631 9.28 BDNF CRHR1 DRD2 HTR1A HTR3A MAOA

Drugs & Therapeutics for Generalized Anxiety Disorder

Drugs for Generalized Anxiety Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 503)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 28981-97-7 2118
2
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
3
Glatiramer Acetate Approved, Investigational Phase 4 147245-92-9 3081884
4
Interferon beta-1b Approved Phase 4,Phase 2,Phase 3 145155-23-3
5
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
6 Racepinephrine Approved Phase 4
7
Nicotine Approved Phase 4 54-11-5 942 89594
8
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
9
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3 2078-54-8 4943
10
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1 79617-96-2 68617
11
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59729-33-8 2771
12
Norepinephrine Approved Phase 4,Phase 3,Phase 2 51-41-2 439260
13
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
14
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1 64-17-5 702
15
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 525-66-6 4946
16
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-23-7 5754 657311
17
Trazodone Approved, Investigational Phase 4,Phase 1 19794-93-5 5533
18
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54910-89-3 3386
19
Ketamine Approved, Vet_approved Phase 4,Phase 2,Early Phase 1 6740-88-1 3821
20
Menthol Approved Phase 4,Phase 3,Phase 2 2216-51-5 16666
21
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
22
Nitrous oxide Approved, Vet_approved Phase 4,Phase 3 10024-97-2 948
23
Buspirone Approved, Investigational Phase 4,Phase 2,Phase 1 36505-84-7 2477
24
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
25
Eszopiclone Approved Phase 4,Phase 2 138729-47-2 969472
26
Lorazepam Approved Phase 4,Phase 3,Phase 2 846-49-1 3958
27
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
28
Ziprasidone Approved Phase 4,Phase 3 146939-27-7 60854
29
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
30
Aripiprazole Approved, Investigational Phase 4,Phase 2 129722-12-9 60795
31
Tiagabine Approved Phase 4,Phase 3 115103-54-3 60648
32
Zolpidem Approved Phase 4 82626-48-0 5732
33
Acamprosate Approved, Investigational Phase 4,Phase 3 77337-76-9 71158
34
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
35
Clonazepam Approved, Illicit Phase 4,Phase 2,Phase 3 1622-61-3 2802
36
Cycloserine Approved Phase 4,Phase 3,Phase 2 68-41-7 401 6234
37
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
38
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
39
Oxytocin Approved, Vet_approved Phase 4,Phase 2 50-56-6 439302 53477758
40
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2 59467-70-8 4192
41
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75614-87-8, 51-45-6 774
42
Mianserin Approved Phase 4,Phase 3,Phase 2 24219-97-4 4184
43
Mirtazapine Approved Phase 4,Phase 3,Phase 2 85650-52-8, 61337-67-5 4205
44
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3 76631-46-4, 113775-47-6 68602 5311068 56032
45
Amitriptyline Approved Phase 4 50-48-6 2160
46
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
47
Fluvoxamine Approved, Investigational Phase 4,Phase 3 54739-18-3 3404 5324346
48
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3 113-45-1 4158
49
Riluzole Approved, Investigational Phase 4,Phase 2 1744-22-5 5070
50 Piracetam Approved Phase 4,Phase 2,Phase 3 7491-74-9

Interventional clinical trials:

(show top 50) (show all 1232)

id Name Status NCT ID Phase Drugs
1 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder Unknown status NCT00662259 Phase 4 Alprazolam (Xanax);Placebo
2 Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD Unknown status NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
3 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Unknown status NCT00176592 Phase 4 Betaseron;Copaxone
4 Sodium Bicarbonate in Cardiopulmonary Resuscitation Unknown status NCT01377337 Phase 4 sodium bicarbonate
5 Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors Unknown status NCT00802919 Phase 4 Varenicline;Placebo for varenicline
6 Effect Site Controlled, Reaction Time Safeguarded, Patient Maintained Sedation With Propofol in Anxious Patients Unknown status NCT00355693 Phase 4
7 Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly Completed NCT00701675 Phase 4 sertraline 50 mg daily;sertraline 100 mg daily;Placebo 50 or 100 mg
8 Escitalopram in Patients With Generalized Anxiety Disorder Completed NCT00902564 Phase 4 Escitalopram
9 A Study of Duloxetine in Elderly Generalized Anxiety Disorder Completed NCT01118780 Phase 4 Duloxetine;Placebo
10 Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD) Completed NCT00219349 Phase 4 escitalopram
11 An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Completed NCT00961298 Phase 4 Duloxetine
12 Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder Completed NCT00235508 Phase 4 Eszopiclone (Lunesta)
13 Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder Completed NCT00624780 Phase 4 Pregabalin;Lorazepam;Pregabalin;Placebo
14 Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder Completed NCT00266409 Phase 4 Niravam;SSRI/SNRI
15 Drug Therapy for Generalized Anxiety Disorder Among the Elderly Completed NCT00105586 Phase 4 Escitalopram
16 Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD) Completed NCT01172652 Phase 4 Ziprasidone;Placebo
17 Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder Completed NCT00113295 Phase 4 Continued Paroxetine CR;Quetiapine;Placebo
18 Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR Completed NCT00183274 Phase 4 Venlafaxine XR;Placebo
19 Chamomile Therapy for Generalized Anxiety Completed NCT00645983 Phase 4
20 A Pilot Study of Cranial Electrotherapy Stimulation[CES] for Generalized Anxiety Disorder Completed NCT00539357 Phase 4
21 Microtuning a Bonafide Treatment for GAD Patients - A Randomized Controlled Trial. Completed NCT02039193 Phase 4
22 Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects Completed NCT01033851 Phase 4
23 A Study of Risperidone Monotherapy in Bipolar Anxiety Completed NCT00167479 Phase 4 risperidone (Risperdal)
24 Aripiprazole for the Treatment of Refractory Anxiety Completed NCT00438386 Phase 4 Aripiprazole
25 Primary Care Intervention Strategy for Anxiety Disorders Completed NCT00347269 Phase 4 Psychotropic medication optimization
26 Lorazepam-Induced Toxicity in the Aged Completed NCT00044642 Phase 4 Lorazepam
27 A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients Completed NCT01201967 Phase 4
28 Switching From an SSRI to Tiagabine(GABITRIL) in Order to Alleviate SSRI Induced Sexual Dysfunction Completed NCT00174850 Phase 4 Gaitril
29 Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro) Completed NCT00296790 Phase 4 zolpidem tartrate
30 Brain Markers of Anxiety Disorders and SSRI/CBT Treatment in Children and Adolescents Completed NCT01160588 Phase 4 Sertraline
31 Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder Completed NCT00892463 Phase 4 Quetiapine (Seroquel) XR
32 Acamprosate in Alcoholics With Comorbid Anxiety or Depression Completed NCT00330174 Phase 4 Acamprosate
33 Black Cohosh as Alternative Therapy for Treating Menopause-Related Anxiety Completed NCT00120458 Phase 4
34 A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and of Quetiapine Fumarate (Seroquel®) as Potentiation SSRI's, and SNRI's Treatment in Major Depression With Anxiety Completed NCT00229645 Phase 4 Quetiapine Fumarate (Seroquel®)
35 Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
36 Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial Completed NCT02263872 Phase 4 Minocycline
37 Identifying Brain and Genetic Markers of Sertraline Treatment Response in People With Social Anxiety Disorder Completed NCT00872131 Phase 4 Sertraline
38 12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder Completed NCT01316302 Phase 4 Pristiq;Placebo
39 Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder Completed NCT00282828 Phase 4 Sertraline;Venlafaxine;Placebo;Clonazepam
40 Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Completed NCT01863459 Phase 4 Lisdexamfetamine Dimesylate;placebo
41 D-Cycloserine Enhancement of Exposure in Social Phobia Completed NCT00633984 Phase 4 D-Cycloserine;Placebo
42 Effectiveness of Integrating Prenatal Care in Reducing HIV/STDs Among Young Pregnant Women Completed NCT00628771 Phase 4
43 An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
44 A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients Completed NCT00619892 Phase 4 quetiapine XR;placebo
45 Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders Completed NCT01631682 Phase 4 Propranolol;Mifepristone;Intranasal oxytocin
46 Escitalopram in Patients With Social Anxiety Disorder Completed NCT00902226 Phase 4 Escitalopram
47 Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder Completed NCT00208741 Phase 4 Gabitril
48 Substudy on the Mechanistic Plausibility of the Clinical Benefits of Adaptive Servo-ventilation Completed NCT01164592 Phase 4
49 The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder Completed NCT00438971 Phase 4 Duloxetine
50 Escitalopram (Lexapro) for the Treatment of Postpartum Depression Completed NCT00833469 Phase 4 Escitalopram

Search NIH Clinical Center for Generalized Anxiety Disorder

Genetic Tests for Generalized Anxiety Disorder

Anatomical Context for Generalized Anxiety Disorder

MalaCards organs/tissues related to Generalized Anxiety Disorder:

39
Breast, Brain, Heart, Testes, Lung, Prostate, Skin

Publications for Generalized Anxiety Disorder

Articles related to Generalized Anxiety Disorder:

(show top 50) (show all 684)
id Title Authors Year
1
Failure in Cognitive Suppression of Negative Affect in Adolescents with Generalized Anxiety Disorder. ( 28747683 )
2017
2
Brain structural changes in late-life generalized anxiety disorder. ( 28837828 )
2017
3
Psychometric analysis of the Generalized Anxiety Disorder scale (GAD-7) in primary care using modern item response theory. ( 28771530 )
2017
4
Using interpersonal process recall to compare patients' accounts of resistance in two psychotherapies for generalized anxiety disorder. ( 28910493 )
2017
5
Integrating iCBT for generalized anxiety disorder into routine clinical care: Treatment effects across the adult lifespan. ( 28926805 )
2017
6
Affective neuroimaging in generalized anxiety disorder: an integrated review. ( 28867941 )
2017
7
Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder. ( 28075650 )
2017
8
Resting state functional connectivity in primary insomnia, generalized anxiety disorder and controls. ( 28500965 )
2017
9
Resting-state functional connectivity in generalized anxiety disorder and social anxiety disorder: Evidence for a dimensional approach. ( 28478685 )
2017
10
Long noncoding RNAs: New evidence for overlapped pathogenesis between major depressive disorder and generalized anxiety disorder. ( 28529365 )
2017
11
Genetics of generalized anxiety disorder and related traits. ( 28867940 )
2017
12
Predictors of remission from generalized anxiety disorder and major depressive disorder. ( 27863710 )
2017
13
Combining Metacognitive Strategies with Traditional Cognitive Behavior Therapy in Generalized Anxiety Disorder: A Case Illustration. ( 28515551 )
2017
14
The influence of Generalized Anxiety Disorder on Executive Functions in children with ADHD. ( 28766128 )
2017
15
Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis. ( 28483071 )
2017
16
Generalized Anxiety Disorder, worry and attention to threat: A systematic review. ( 28448826 )
2017
17
The history of generalized anxiety disorder as a diagnostic category. ( 28867935 )
2017
18
Biological markers of generalized anxiety disorder. ( 28867939 )
2017
19
Spontaneous alterations of regional brain activity in patients with adult generalized anxiety disorder. ( 28790831 )
2017
20
Prefrontal and amygdala engagement during emotional reactivity and regulation in generalized anxiety disorder. ( 28501740 )
2017
21
Reduction in Costs after Treating Comorbid Panic Disorder with Agoraphobia and Generalized Anxiety Disorder. ( 28418834 )
2017
22
Childhood adversity, adult stress, and the risk of major depression or generalized anxiety disorder in US soldiers: a test of the stress sensitization hypothesis. ( 28443533 )
2017
23
Long noncoding RNA as an indicator differentiating schizophrenia from major depressive disorder and generalized anxiety disorder in nonpsychiatric hospital. ( 28092449 )
2017
24
The association of generalized anxiety disorder and Somatic Symptoms with frequent attendance to health care services: A cross-sectional study from the Northern Finland Birth Cohort 1966. ( 28792287 )
2017
25
Error-Specific Cognitive Control Alterations in Generalized Anxiety Disorder. ( 28871288 )
2017
26
Environmental transmission of generalized anxiety disorder from parents to children: worries, experiential avoidance, and intolerance of uncertainty. ( 28867938 )
2017
27
Prevalence of generalized anxiety disorder and major depression in health-care givers of disabled patients in Majmaah and Shaqra cities, Kingdom of Saudi Arabia. ( 28936144 )
2017
28
Client Retrospective Accounts of Corrective Experiences in Motivational Interviewing Integrated With Cognitive Behavioral Therapy for Generalized Anxiety Disorder. ( 28072459 )
2017
29
In the grip of worry: cerebral blood flow changes during worry induction and reappraisal in late-life generalized anxiety disorder. ( 28949338 )
2017
30
Emotion-focused perspective on generalized anxiety disorder: A qualitative analysis of clients' in-session presentations. ( 28893153 )
2017
31
In the grip of worry: cerebral blood flow changes during worry induction and reappraisal in late-life generalized anxiety disorder. ( 28809854 )
2017
32
Association of Panic Disorder, Generalized Anxiety Disorder, and Benzodiazepine Treatment During Pregnancy With Risk of Adverse Birth Outcomes. ( 28903165 )
2017
33
Repetitive transcranial magnetic stimulation of the right dorsal lateral prefrontal cortex in the treatment of generalized anxiety disorder: A randomized, double-blind sham controlled clinical trial. ( 28533148 )
2017
34
The Association between Generalized Anxiety Disorder, Subthreshold Anxiety Symptoms and Fear of Falling among Older Adults: Preliminary Results from a Pilot Study. ( 28452660 )
2017
35
Sequential Treatment of Comorbid Insomnia and Generalized Anxiety Disorder. ( 27111542 )
2016
36
Developmental risk factors in generalized anxiety disorder and panic disorder. ( 27466747 )
2016
37
Impaired Retrieval Inhibition of Threat Material in Generalized Anxiety Disorder. ( 27042388 )
2016
38
Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. ( 27912875 )
2016
39
Neurasthenia, Generalized Anxiety Disorder, and the Medicalization of Worry in a Vietnamese Psychiatric Hospital. ( 27113055 )
2016
40
Which factors influence onset and latency to treatment in generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder? ( 27384739 )
2016
41
Aberrant regional neural fluctuations and functional connectivity in generalized anxiety disorder revealed by resting-state functional magnetic resonance imaging. ( 27163197 )
2016
42
Stress system dysregulation in pediatric generalized anxiety disorder associated with comorbid depression. ( 27982510 )
2016
43
An Underlying Common Factor, Influenced by Genetics and Unique Environment, Explains the Covariation Between Major Depressive Disorder, Generalized Anxiety Disorder, and Burnout: A Swedish Twin Study. ( 27620693 )
2016
44
Are Major Depression and Generalized Anxiety Disorder Associated With Oligohydramnios in Pregnant Women? A Case-Control Study. ( 27357862 )
2016
45
Adaptation and initial validation of the Patient Health Questionnaire - 9 (PHQ-9) and the Generalized Anxiety Disorder - 7 Questionnaire (GAD-7) in an Arabic speaking Lebanese psychiatric outpatient sample. ( 27031595 )
2016
46
Rapid detection of generalized anxiety disorder and major depression in epilepsy: Validation of the GAD-7 as a complementary tool to the NDDI-E in a French sample. ( 26994447 )
2016
47
Improvements in emotion regulation following repetitive transcranial magnetic stimulation for generalized anxiety disorder. ( 27467027 )
2016
48
Taxonicity and network structure of generalized anxiety disorder and major depressive disorder: An admixture analysis and complex network analysis. ( 27100054 )
2016
49
Generalized Anxiety Disorder and Hypoglycemia Symptoms Improved with Diet Modification. ( 27493821 )
2016
50
Intolerance of uncertainty, causal uncertainty, causal importance, self-concept clarity and their relations to generalized anxiety disorder. ( 27113431 )
2016

Variations for Generalized Anxiety Disorder

Expression for Generalized Anxiety Disorder

Search GEO for disease gene expression data for Generalized Anxiety Disorder.

Pathways for Generalized Anxiety Disorder

Pathways related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
2
Show member pathways
11.94 BDNF DRD2 HTR1A
3 11.71 BDNF HTR1A HTR2A HTR3A MAOA SLC6A4
4 11.69 HTR1A HTR2A HTR3A MAOA SLC6A4 TPH1
5
Show member pathways
11.61 BDNF DRD2 MAOA
6
Show member pathways
11.56 DRD2 HTR1A HTR2A
7
Show member pathways
11.07 MAOA SLC6A2 SLC6A4
8
Show member pathways
10.86 MAOA SLC6A4
9
Show member pathways
10.75 MAOA TPH1
10 10.55 HTR1A HTR2A HTR3A MAOA SLC6A4 TPH1

GO Terms for Generalized Anxiety Disorder

Cellular components related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.43 CRHR1 DRD2 HTR1A HTR2A SLC6A2 SLC6A4
2 neuron projection GO:0043005 8.92 RGS2 SLC6A2 SLC6A4 TPH1

Biological processes related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of insulin secretion GO:0046676 9.56 DRD2 PSMD9
2 response to axon injury GO:0048678 9.55 DRD2 TSPO
3 regulation of dopamine secretion GO:0014059 9.54 DRD2 HTR2A
4 behavioral response to cocaine GO:0048148 9.52 DRD2 HTR2A
5 temperature homeostasis GO:0001659 9.51 DRD2 HTR2A
6 response to pain GO:0048265 9.49 SLC6A2 TSPO
7 vasoconstriction GO:0042310 9.48 HTR1A SLC6A4
8 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.46 DRD2 HTR2A
9 negative regulation of voltage-gated calcium channel activity GO:1901386 9.43 CRHR1 DRD2
10 behavior GO:0007610 9.4 HTR1A HTR2A
11 regulation of behavior GO:0050795 9.37 HTR1A HTR2A
12 monoamine transport GO:0015844 9.32 SLC6A2 SLC6A4
13 dopamine uptake involved in synaptic transmission GO:0051583 9.26 SLC6A2 SLC6A4
14 regulation of hormone secretion GO:0046883 9.16 HTR1A HTR2A
15 response to drug GO:0042493 9.02 DRD2 HTR2A SLC6A2 SLC6A4 TSPO
16 serotonin receptor signaling pathway GO:0007210 8.96 HTR1A HTR2A

Molecular functions related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 beta-tubulin binding GO:0048487 9.4 RGS2 SLC6A2
2 neurotransmitter receptor activity GO:0030594 9.37 HTR1A HTR2A
3 G-protein coupled serotonin receptor activity GO:0004993 9.32 HTR1A HTR2A
4 G-protein alpha-subunit binding GO:0001965 9.26 HTR2A RGS2
5 monoamine transmembrane transporter activity GO:0008504 9.16 SLC6A2 SLC6A4
6 dopamine:sodium symporter activity GO:0005330 8.96 SLC6A2 SLC6A4
7 serotonin binding GO:0051378 8.8 HTR1A HTR2A HTR3A

Sources for Generalized Anxiety Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....